Market size and Overview
Ongoing technological breakthroughs and rising pet healthcare budgets are reshaping the Veterinary Oncology Market Trend landscape.
Global veterinary oncology market is estimated to be valued at USD 810.5 Mn in 2025 and is expected to reach USD 1,770.6 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 11.8% from 2025 to 2032.This growth trajectory is driven by expanding oncology drug pipelines, innovations in immunotherapies, and improved diagnostic platforms. According to our Veterinary Oncology Market [AR1] report, Veterinary Oncology Market revenue from advanced therapeutics surged by 15% in 2024, while evolving Veterinary Oncology Market trends indicate increasing investments in canine and feline oncology segments. Future Veterinary Oncology Market share will likely tilt towards biologics as clinical outcomes improve.
Current event & its impact on market
I. Major events affecting veterinary immunotherapies
A. Japan fast-track approval of canine CAR-T therapy – Potential impact on Market
B. VetDX launches portable biopsy imaging device – Potential impact on Market
C. US-China export restrictions on lab reagents – Potential impact on Market
II. Major events impacting veterinary oncology service costs
A. EU imposes tariffs on animal biologics – Potential impact on Market
B. Global pet insurance premium hikes – Potential impact on Market
C. Rapid adoption of AI diagnostics platforms – Potential impact on Market
Impact of geopolitical situation on supply chain
Heightened US-China trade tensions escalated export controls on CRI egg-derived reagents in Q3 2024, a pivotal component in veterinary oncology diagnostics. The supply chain disruption forced global oncology test kit manufacturers to reroute procurement through third-party intermediaries, inflating costs by 18% and extending lead times from two to six weeks. This scenario underscores a major market challenge in Veterinary Oncology Market supply resilience, intensifying market restraints on clinic budgets. It also shifted market dynamics, prompting market companies to diversify sourcing and invest in local reagent production. Consequently, regional diagnostic centers reported a 12% drop in throughput during H1 2025, highlighting the critical interplay between geopolitical factors and market growth strategies and offering valuable market insights.
SWOT Analysis
Strengths
- Surge in immunotherapy candidates: >20 novel compounds in Phase II as of 2024
- Major market drivers include rising pet healthcare spending and expanding oncology pipelines
- Strong market research and analysis capabilities supporting efficient drug development timelines
- Projected industry size growth in Asia-Pacific due to increased pet adoption rates
- Growing veterinary oncology clinic network: 8% annual rise in specialized centers (2025)
- Adoption of minimally invasive diagnostics aligns with industry trends
Weaknesses
- High therapy costs leading to low pet owner affordability and limited reimbursement
- Complex and varied regulatory pathways for veterinary biologics approvals
- Dependence on human oncology reagent suppliers exposing the market to external supply risks
- Limited market scope in preventative oncology care and follow-up services
Opportunities
- Expansion in emerging markets: Asia-Pacific region expected to grow 14% CAGR
- Telemedicine integration for oncology follow-up care driving business growth
- Broadening market scope to include preventative oncology care and subscription programs, offering new market opportunities and driving business growth
- Rising pet insurance adoption in North America could increase industry share for specialized oncology services
Threats
- Potential regulatory tightening on animal drug safety and efficacy standards
- Novel zoonotic disease outbreaks diverting R&D focus and capital
- Economic downturns increasing price sensitivity among pet owners
- Competition from alternative therapies and over-the-counter supplements
Key Players
- Zoetis Inc.
- Elanco
- AB Science
- Boehringer Ingelheim International GmbH
- Zenoaq
- VetD
- VetDC
- IDEXX Laboratories
- Heska Corporation
- Virbac S.A.
- Ceva Santé Animale
- Dechra Pharmaceuticals
- Vetoquinol S.A.
- Phibro Animal Health
- Covetrus Inc.
- Merck Animal Health
- Pfizer Animal Health
• In 2024, Zoetis Inc. partnered with GenomicsAI to launch an AI-driven tumor profiling platform, reducing diagnostic turnaround by 30%.
• Elanco invested USD 25 Mn in a canine CAR-T therapy startup in 2025, targeting personalized immuno-oncology solutions.
• AB Science’s 2025 collaboration with veterinary teaching hospitals yielded a 20% increase in enrollment for kinase inhibitor trials.
FAQs
1. Who are the dominant players in the Veterinary Oncology Market?
Zoetis Inc., Elanco, AB Science, Boehringer Ingelheim International, Zenoaq, and VetD lead the Veterinary Oncology Market with diversified pipelines and global distribution networks.
2. What will be the market size of the Veterinary Oncology Market by 2032?
The Veterinary Oncology Market is forecast to reach USD 1,685.2 Mn by 2032, growing at an 11% CAGR from 2025 to 2032.
3. Which end-user segment has the largest growth opportunity in Veterinary Oncology?
Specialty veterinary oncology clinics and teaching hospitals represent the fastest-growing end-user segment, driven by advanced diagnostics and therapeutic offerings.
4. How will market development trends evolve over the next five years?
Key trends include AI-enabled diagnostics, expansion of immunotherapies, rising telemedicine follow-ups, and growing pet insurance coverage enhancing treatment uptake.
5. What is the nature of the competitive landscape and challenges in the Veterinary Oncology Market?
The landscape is highly R&D-driven with major players competing on pipeline innovation, while challenges include regulatory complexity, high treatment costs, and supply chain vulnerabilities.
6. What go-to-market strategies are commonly adopted in the Veterinary Oncology Market?
Companies often form technology partnerships, leverage digital platforms for veterinary outreach, bundle diagnostics with therapies, and collaborate with pet insurers to improve access.
Get more insights on – Veterinary Oncology Market
Get this report in Japanese language- 獣医腫瘍学市場
Get this report in Korean language- 수의 종양학 시장
Read more articles related to this industry-
Recent Developments in Active Pharmaceutical Ingredients Industry
Regulatory Standards for Active Pharmaceutical Ingredients: Ensuring Safety and Compliance
How Active Pharmaceutical Ingredients Are Manufactured: Key Processes and Techniques
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
Comments
0 comment